| Symbol | STOK |
|---|---|
| Name | STOKE THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 45 WIGGINS AVENUE, BEDFORD, Massachusetts, 01730, United States |
| Telephone | +1 781 430-8200 |
| Fax | — |
| — | |
| Website | https://www.stoketherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001623526 |
| Description | Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Additional info from NASDAQ: |
Harrison Seth Loring 🟡 adjusted position in 0 shares (16 derivative) of Stoke Therapeutics, Inc. (STOK) at $40.37 ($6.4M) Transaction Date: Jul 16, 2026 | Filing ID: 000006
Read moreMcCauley Thomas 🟢 acquired 225.0K shares (1 derivative) of Stoke Therapeutics, Inc. (STOK) at $29.91 ($6.7M) Transaction Date: Jul 15, 2026 | Filing ID: 000008
Read moreNew Form 3 - Stoke Therapeutics, Inc. <b>Filed:</b> 2026-07-17 <b>AccNo:</b> 0001858760-26-000007 <b>Size:</b> 10 KB
Read moreStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Read moreTicho Barry 🔴 sold 7.2K shares of Stoke Therapeutics, Inc. (STOK) at $33.27 Transaction Date: Jul 01, 2026 | Filing ID: 000015
Read more(10% Negative) STOKE THERAPEUTICS, INC. (STOK) Announces Delay in treatment Trials for Dravet syndrome Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreStoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Read more📋 JONATHAN D ALLAN (Officer) plans to sell 1K shares of STOKE THERAPEUTICS INC (at $30.00 each, total $44K) Filed: Jun 16, 2026 | ID: 006194
Read moreStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Read moreTZIANABOS ARTHUR 🟢 acquired 17.8K shares (1 derivative) of Stoke Therapeutics, Inc. (STOK) at $29.46 Transaction Date: Jun 03, 2026 | Filing ID: 000004
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06872125 | A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorev… | Phase3 | Dravet Syndrome | Recruiting | 2025-06-04 | 2028-10-01 | ClinicalTrials.gov |
| NCT04740476 | An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome | Phase2 | Dravet Syndrome | Active_Not_Recruiting | 2021-01-20 | 2029-03-31 | ClinicalTrials.gov |
| NCT04442295 | An Open-Label Study to Investigate the Safety of Single and Multiple Ascending … | Phase1 | Dravet Syndrome | Completed | 2020-06-29 | 2023-11-14 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Sham Comparator | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| zorevunersen | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| Sham Comparator | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| zorevunersen | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| Sham Comparator | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| zorevunersen | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| Sham Comparator | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| zorevunersen | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| Sham Comparator | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| zorevunersen | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| Sham Comparator | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| zorevunersen | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| Sham Comparator | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| zorevunersen | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| Sham Comparator | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| zorevunersen | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| STK-001 - Multiple Ascending Doses | Other | Phase PHASE1 | Dravet Syndrome | COMPLETED | NCT04442295 |
| STK-001 - Single Ascending Doses | Other | Phase PHASE1 | Dravet Syndrome | COMPLETED | NCT04442295 |
| zorevunersen (STK-001) | Other | Phase PHASE2 | Dravet Syndrome | ACTIVE_NOT_RECRUITING | NCT04740476 |
| Sham Comparator | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| zorevunersen | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| Sham Comparator | OTHER | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| zorevunersen | DRUG | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| zorevunersen (STK-001) | DRUG | Phase PHASE2 | Dravet Syndrome | ACTIVE_NOT_RECRUITING | NCT04740476 |
| STK-001 - Multiple Ascending Doses | DRUG | Phase PHASE1 | Dravet Syndrome | COMPLETED | NCT04442295 |
| STK-001 - Single Ascending Doses | DRUG | Phase PHASE1 | Dravet Syndrome | COMPLETED | NCT04442295 |